Tequin Merits Black Box Reconsideration For Dysglycemia, Editorial Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol’s gatifloxacin is “strongly associated with subsequent hospital care for hypoglycemia and hyperglycemia,” NEJM study finds.
You may also be interested in...
Bristol Discontinues Tequin, Citing Lack Of Commercial Potential
The antibiotic was the subject of recent safety concerns.
Nexavar “Very Competitive” With Pfizer’s Sutent, Bayer Says
Bayer’s kidney cancer drug brought in $25.2 mil. (€20 mil.) in the first quarter following its approval late last year.